Abstract | BACKGROUND: METHODS: In this study, MAPT expression was analyzed by immunohistochemistry on a tissue microarray containing 17,747 prostate cancers. RESULTS: MAPT was absent in normal prostate epithelial cells but detectable in 1004 (8.2%) of 12,313 interpretable cancers. Its expression was associated with advanced tumor stage, high Gleason grade, positive lymph nodes, and early biochemical recurrence (p < 0.0001 each). For example, MAPT was found in 3.6% of 2072 Gleason ≤3 + 3 cancers but in 14.4% of 704 Gleason ≥4 + 4 cancers. High-level MAPT staining was also linked to TMPRSS2:ERG fusions (p < 0.0001). MAPT staining was seen in 15.2 and 16% of cancers with TMPRSS2:ERG fusion detected by immunohistochemistry and fluorescence in-situ hybridization, but in only 3.5 and 3.9% of cancers without ERG staining or ERG rearrangements. Moreover, an association was found between MAPT expression and PTEN deletions, with 19% MAPT positivity in 948 PTEN deleted cancers but only 7% MAPT positivity in 3895 tumors with normal PTEN copy numbers (p < 0.0001). Multivariate analysis revealed that the prognostic value of MAPT was independent from established parameters. Conventional large section analyses showed intratumoral MAPT heterogeneity in all three analyzed cancers. CONCLUSIONS: The results of our study identify MAPT, as a moderate prognostic marker in prostate cancer, whose clinical impact, however, may be limited due to the rarity and heterogeneity of its expression.
|
Authors | Cornelia Schroeder, Jan Grell, Claudia Hube-Magg, Martina Kluth, Dagmar Lang, Ronald Simon, Doris Höflmayer, Sarah Minner, Eike Burandt, Till S Clauditz, Franziska Büscheck, Frank Jacobsen, Hartwig Huland, Markus Graefen, Thorsten Schlomm, Guido Sauter, Stefan Steurer |
Journal | BMC cancer
(BMC Cancer)
Vol. 19
Issue 1
Pg. 193
(Mar 01 2019)
ISSN: 1471-2407 [Electronic] England |
PMID | 30823906
(Publication Type: Journal Article)
|
Chemical References |
- MAPT protein, human
- Oncogene Proteins, Fusion
- TMPRSS2-ERG fusion protein, human
- tau Proteins
- PTEN Phosphohydrolase
- PTEN protein, human
- KLK3 protein, human
- Kallikreins
- Prostate-Specific Antigen
|
Topics |
- Humans
- Immunohistochemistry
- Kallikreins
(blood)
- Lymph Nodes
(pathology)
- Male
- Multivariate Analysis
- Neoplasm Grading
- Neoplasm Recurrence, Local
(blood, epidemiology)
- Neoplasm Staging
- Oncogene Proteins, Fusion
(genetics)
- PTEN Phosphohydrolase
(genetics)
- Prognosis
- Proportional Hazards Models
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(genetics, metabolism, pathology)
- tau Proteins
(metabolism)
|